Inovio Pharmaceuticals, Inc. (INO)

$10.96

-0.29

(-2.58%)

Market is closed - opens 7 PM, 24 May 2024

Insights on Inovio Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 388.44K → 102.65K (in $), with an average decrease of 73.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -25.00M → -30.46M (in $), with an average decrease of 21.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.6% return, outperforming this stock by 17.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.9% return, outperforming this stock by 319.1%

Performance

  • $10.86
    $11.41
    $10.96
    downward going graph

    0.91%

    Downside

    Day's Volatility :4.82%

    Upside

    3.94%

    downward going graph
  • $3.89
    $14.75
    $10.96
    downward going graph

    64.51%

    Downside

    52 Weeks Volatility :73.63%

    Upside

    25.69%

    downward going graph

Returns

PeriodInovio Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
34.31%
-2.0%
0.0%
6 Months
117.98%
10.5%
0.0%
1 Year
50.59%
12.2%
0.0%
3 Years
-87.24%
16.4%
-20.6%

Highlights

Market Capitalization
291.5M
Book Value
$3.65
Earnings Per Share (EPS)
-5.64
PEG Ratio
0.0
Wall Street Target Price
18.92
Profit Margin
0.0%
Operating Margin TTM
-16868.64%
Return On Assets TTM
-38.21%
Return On Equity TTM
-85.09%
Revenue TTM
717.1K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-17.7%
Gross Profit TTM
-177.4M
EBITDA
-118.6M
Diluted Eps TTM
-5.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.42
EPS Estimate Next Year
-3.19
EPS Estimate Current Quarter
-1.0
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Hold
    0
    0%Buy
    54%Hold
    45%Sell
Based on 11 Wall street analysts offering stock ratings for Inovio Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
6
6
6
Sell
5
5
6

Analyst Forecast

What analysts predicted

Upside of 72.63%

Current $10.96
Target $18.92

Technicals Summary

Sell

Neutral

Buy

Inovio Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
7.87%
117.98%
50.59%
-87.24%
-71.98%
Moderna, Inc.
Moderna, Inc.
50.68%
108.88%
24.64%
-0.1%
651.31%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
8.17%
22.83%
32.98%
95.93%
213.72%
Novo Nordisk A/s
Novo Nordisk A/s
7.46%
28.56%
67.6%
231.87%
458.02%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.49%
27.69%
35.03%
113.43%
162.44%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
NA
NA
0.0
-4.42
-0.85
-0.38
NA
3.65
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.07
29.07
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.22
46.22
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.06
29.06
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Hold
$291.5M
-71.98%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$62.6B
651.31%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.4B
213.72%
29.07
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$598.1B
458.02%
46.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.5B
162.44%
29.06
39.46%

Institutional Holdings

  • Vanguard Group Inc

    6.15%
  • Millennium Management LLC

    1.03%
  • GSA Capital Partners LLP

    0.31%
  • Green Alpha Advisors, LLC

    0.14%
  • Citigroup Inc

    0.14%
  • American Century Companies Inc

    0.08%

Company Information

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Organization
Inovio Pharmaceuticals, Inc.
Employees
122
CEO
Dr. Jacqueline E. Shea Ph.D.
Industry
Health Technology

FAQs